-
Tytuł:
-
Progression of liver fibrosis following acute hepatitis C virus infection in HIV-positive MSM.
-
Autorzy:
-
Newsum AM; Department of Infectious Diseases, Research and Prevention, Public Health Service of Amsterdam.; Division of Infectious Diseases, Amsterdam Infection and Immunity Institute.
Kooij KW; Department of Global Health, Amsterdam Public Health Research Institute, Amsterdam UMC, University of Amsterdam.; Amsterdam Institute for Global Health and Development, Amsterdam, The Netherlands.
Boyd A; Department of Infectious Diseases, Research and Prevention, Public Health Service of Amsterdam.; INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Sorbonne Université, Paris, France.
Smit C; Stichting HIV Monitoring, Amsterdam, The Netherlands.
Wit FWNM; Division of Infectious Diseases, Amsterdam Infection and Immunity Institute.; Department of Global Health, Amsterdam Public Health Research Institute, Amsterdam UMC, University of Amsterdam.; Amsterdam Institute for Global Health and Development, Amsterdam, The Netherlands.; Stichting HIV Monitoring, Amsterdam, The Netherlands.
van der Meer JTM; Division of Infectious Diseases, Amsterdam Infection and Immunity Institute.
Prins M; Department of Infectious Diseases, Research and Prevention, Public Health Service of Amsterdam.; Division of Infectious Diseases, Amsterdam Infection and Immunity Institute.
Reiss P; Division of Infectious Diseases, Amsterdam Infection and Immunity Institute.; Department of Global Health, Amsterdam Public Health Research Institute, Amsterdam UMC, University of Amsterdam.; Amsterdam Institute for Global Health and Development, Amsterdam, The Netherlands.; Stichting HIV Monitoring, Amsterdam, The Netherlands.
van der Valk M; Division of Infectious Diseases, Amsterdam Infection and Immunity Institute.
-
Corporate Authors:
-
MOSAIC study group, ATHENA observational HIV cohort and NVHB-SHM hepatitis working group
-
Źródło:
-
AIDS (London, England) [AIDS] 2019 Apr 01; Vol. 33 (5), pp. 833-844.
-
Typ publikacji:
-
Journal Article; Observational Study; Research Support, Non-U.S. Gov't
-
Język:
-
English
-
Imprint Name(s):
-
Publication: 1998- : London, England : Lippincott Williams & Wilkins
Original Publication: London : Gower Academic Journals, c1987-
-
MeSH Terms:
-
Disease Progression*
Homosexuality, Male*
Coinfection/*virology
HIV Infections/*physiopathology
Hepatitis C/*pathology
Liver Cirrhosis/*pathology
Adult ; Hepatitis C/complications ; Humans ; Liver Cirrhosis/etiology ; Liver Cirrhosis/virology ; Male ; Markov Chains ; Netherlands/epidemiology ; Retrospective Studies
-
Entry Date(s):
-
Date Created: 20190117 Date Completed: 20200518 Latest Revision: 20200518
-
Update Code:
-
20240104
-
DOI:
-
10.1097/QAD.0000000000002138
-
PMID:
-
30649050
-
Background: Whether continued, accelerated liver fibrosis progression occurs following acute hepatitis C virus infection (AHCVI) in HIV-positive MSM is unknown.
Design and Methods: HIV-positive MSM from the AIDS Therapy Evaluation in the Netherlands and MSM Observational Study for Acute Infection with Hepatitis C-cohorts with primary AHCVI and at least one fibrosis-4 (FIB-4) measurement less than 2 years before and 1 year after estimated AHCVI were included. Mixed-effect linear models were used to evaluate (time-updated) determinants of FIB-4 levels over time. Determinants of transitioning to and from FIB-4 ≤ 1.45 and > 1.45 were examined using multistate Markov models.
Results: Of 313 MSM, median FIB-4 measurements per individual was 12 (interquartile range = 8-18) and median follow-up following AHCVI was 3.5 years (interquartile range = 1.9-5.6). FIB-4 measurements averaged at 1.00 [95% confidence interval (CI) = 0.95-1.05] before AHCVI, 1.31 (95% CI = 1.25-1.38) during the first year of AHCVI and 1.10 (95% CI = 1.05-1.15) more than 1 year after AHCVI. Mean FIB-4 more than 1 year after AHCVI was higher for chronically infected patients compared with those successfully treated (P = 0.007). Overall FIB-4 scores were significantly higher with older age, lower CD4 cell count, longer duration from HIV-diagnosis or AHCVI, and nonresponse to HCV-treatment. At the end of follow-up, 60 (19.2%) and eight MSM (2.6%) had FIB-4 between 1.45-3.25 and ≥ 3.25, respectively. Older age, lower CD4 cell count and detectable HIV-RNA were significantly associated with higher rates of progression to FIB-4 > 1.45, whereas older age, longer duration from HIV-diagnosis and nonresponse to HCV-treatment were significantly associated with lower rates of regression to FIB-4 ≤ 1.45.
Conclusion: In this population of HIV-positive MSM, FIB-4 scores were higher during the first year of AHCVI, but FIB-4 ≥ 3.25 was uncommon by the end of follow-up. Well controlled HIV-infection appears to attenuate FIB-4 progression.
